Sreedhar Mandayam, MD
Enriched profileProfessor, Section of Nephrology, The University of Texas MD Anderson Cancer Center · The University of Texas MD Anderson Cancer Center
Sreedhar Mandayam is Professor, Section of Nephrology, The University of Texas MD Anderson Cancer Center at The University of Texas MD Anderson Cancer Center. OpenAlex indexes 114 publications with 3,211 citations (h-index 28); ClinicalTrials.gov lists 6 registered studies with this person as an investigator.
Data verified 17 Oct 2026
Overview
Updated 18 Oct 2026
Sreedhar Mandayam, M.D., is Professor, Section of Nephrology, The University of Texas MD Anderson Cancer Center. The public record shows 114 publications with 3,211 citations (h-index 28), centered on Chronic Kidney Disease and Diabetes, Renal Diseases and Glomerulopathies, Dialysis and Renal Disease Management. It also documents an investigator role on 6 registered clinical trials, industry payments reported by 48 companies.
- Most recent indexed publication: 2021 · Blood
- Top research focus: Chronic Kidney Disease and Diabetes
- 6 registered trials on ClinicalTrials.gov
- Open Payments reporting from 48 companies
Generated from the cited public record · current as of 18 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 2 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 39.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 18 Oct 2026
Listed as an investigator on 6 registered studies on ClinicalTrials.gov. The most recent:
- Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN
Sponsor: Novartis Pharmaceuticals
- Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN
Sponsor: Novartis Pharmaceuticals
Industry payments
Updated 18 Oct 2026
48 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Calliditas Therapeutics US Inc.Program year202562 payments$57,938openpaymentsdata.cms.gov ↗
- KYOWA KIRIN, INC.Program year20259 payments
- Otsuka America Pharmaceutical, Inc.Program year20258 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
35.1%Loop diuretic13.2%Furosemide100%Part D<11 patientsAngiotensin receptor blocker (ARB)12.6%Losartan Potassium100%Part D<11 patients+ 1 more class in this area
Musculoskeletal
29.9%Xanthine oxidase inhibitor29.9%Allopurinol100%Part D≥15 patientsMetabolism & gastrointestinal
22.4%SGLT2 inhibitor22.4%Jardiance72%Farxiga28%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 18 Oct 2026
5 congress contributions (2018–2022) across AACE, ASCO per OpenAlex. The most recent:
- Real-world analysis of safety and efficacy of CAR T-cell therapy in patients with lymphoma with decreased renal function.
ASCO Annual Meeting
ASCO2022Co-author - Acute kidney injury and major outcomes in cancer patients with no history of chronic kidney disease (CKD) with coronavirus 2019 (COVID-19) infection.
ASCO Annual Meeting
ASCO2021Co-authorOnline-only - Clinical characteristics and outcomes of cancer patients with chronic kidney disease and coronavirus disease 2019.
ASCO Annual Meeting
ASCO2021Co-authorOnline-only
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 18 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Renal Replacement Therapy in Patients With Stage IV Cancer Admitted to the Intensive Care Unit With Acute Kidney Injury at a Comprehensive Cancer Center Was Not Associated With Survival.
The American journal of hospice & palliative care
Article2020
Most-cited works
by citation count (OpenAlex)Network
Updated 18 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 18 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Mentions by others
where others cite or feature them- Other
faculty.mdanderson.org/profiles/sreedhar_mandayam.html
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 18 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- M.R.C.P1999verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Editorial & leadership roles
journal and society appointments- Fellow
American Society of Nephrology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Secondary affiliations
appointments beyond the home institution- Patient Experience Officer
Mays ACB Clinic Nephrology, UT MD Anderson Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗ - Public Safety and Quality Officer
Nephrology Division, UT MD Anderson Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗ - Member
Baylor College of Medicine Eisenberg Center for Clinical Decisions & Communication Science
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Toni Choueiri, MD
Dana-Farber Cancer Institute
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Fred Saad, MD
Centre hospitalier de l'Université de Montréal (CHUM)